{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T05:38:30Z","timestamp":1781415510039,"version":"3.54.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,1,2]],"date-time":"2017-01-02T00:00:00Z","timestamp":1483315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science (JSPS) KAKENHI","award":["15H04903"],"award-info":[{"award-number":["15H04903"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aim of this study was to prospectively assess 5-year health-related quality of life (HRQOL) of patients treated with carbon ion radiotherapy (C-ion RT) for clinically localized prostate cancer. A total of 417 patients received carbon ion radiotherapy at a total dose of 63\u201366 Gray-equivalents (GyE) in 20 fractions over 5 weeks, and neoadjuvant and adjuvant androgen deprivation therapy (ADT) were administered for intermediate and high-risk patients. A HRQOL assessment was performed at five time points (immediately before the initiation of C-ion RT, immediately after, and at 12, 36 and 60 months after completion of C-ion RT) using Functional Assessment of Cancer Therapy (FACT) questionnaires. FACT-G and FACT-P scores were significantly decreased; however, the absolute change after 60 months was minimal. The transient decreases in the Trial Outcome Index (TOI) score returned to their baseline levels. Use of ADT, presence of adverse events, and biochemical failure were related to lower scores. Scores of subdomains of FACT instruments indicated characteristic changes. The pattern of HRQOL change after C-ion RT was similar to that of other modalities. Further controlled studies focusing on a HRQOL in patients with prostate cancer are warranted.<\/jats:p>","DOI":"10.1093\/jrr\/rrw122","type":"journal-article","created":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T07:06:33Z","timestamp":1480403193000},"page":"260-266","source":"Crossref","is-referenced-by-count":18,"title":["Five-year quality of life assessment after carbon ion radiotherapy for prostate cancer"],"prefix":"10.1093","volume":"58","author":[{"given":"Katsuya","family":"Maruyama","sequence":"first","affiliation":[{"name":"Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan"},{"name":"Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Nomiya","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kanagawa Cancer Center, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Katoh","sequence":"additional","affiliation":[{"name":"Gunma Heavy-ion Medical Center, Gunma University, Gunma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Tsukuba Faculty of Medicine, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Kamada","sequence":"additional","affiliation":[{"name":"Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Wakatsuki","sequence":"additional","affiliation":[{"name":"Department of Radiology, Jichi Medical University, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Akakura","sequence":"additional","affiliation":[{"name":"Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Shimazaki","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Department of Radiology and Radiation Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Tsujii","sequence":"additional","affiliation":[{"name":"Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Working Group for Genitourinary Tumors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"key":"2020010903182658500_rrw122C1","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0360-3016(01)01730-8","article-title":"Short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life","volume":"51","author":"Kupelian","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903182658500_rrw122C2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijrobp.2011.11.047","article-title":"Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer","volume":"84","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903182658500_rrw122C3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2012.07.004","article-title":"High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature result","volume":"85","author":"Zamboglou","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903182658500_rrw122C4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/jrr\/rrt027","article-title":"The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer","volume":"54","author":"Yoshioka","year":"2013","journal-title":"J Radiat Res"},{"key":"2020010903182658500_rrw122C5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ijrobp.2012.01.072","article-title":"Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions","volume":"84","author":"Okada","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903182658500_rrw122C6","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ijrobp.2008.02.035","article-title":"Quality of life in men treated with carbon ion therapy for prostare cancer","volume":"72","author":"Wakatsuki","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903182658500_rrw122C7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/iju.12294","article-title":"Health-related quality of life after carbon-ion radiotherapy for prostate cancer: a 3-year prospective study","volume":"21","author":"Katoh","year":"2014","journal-title":"Int J Urol"},{"key":"2020010903182658500_rrw122C8","volume-title":"International Union Against Cancer. TNM classification of malignant tumours","author":"Sobin","year":"1997","edition":"5th edn."},{"key":"2020010903182658500_rrw122C9","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ijrobp.2005.04.022","article-title":"Hypofractionated radiotherapy with carbon ion beams for prostate cancer","volume":"63","author":"Tsuji","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903182658500_rrw122C10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.radonc.2006.08.015","article-title":"Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study","volume":"81","author":"Ishikawa","year":"2006","journal-title":"Radiother Oncol"},{"key":"2020010903182658500_rrw122C11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jjco\/hyl030","article-title":"Monotherapy with carbon ion radiation for localized prostate cancer","volume":"36","author":"Shimazaki","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"2020010903182658500_rrw122C12","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2006.06.056","article-title":"Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer","volume":"66","author":"Ishikawa","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903182658500_rrw122C13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"2020010903182658500_rrw122C14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0895-4356(01)00477-2","article-title":"What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592","volume":"55","author":"Cella","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"2020010903182658500_rrw122C15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Researchand Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903182658500_rrw122C16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0360-3016(03)00439-5","article-title":"Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias","volume":"57","author":"Pickles","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903182658500_rrw122C17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1023\/A:1013851216181","article-title":"Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese","volume":"10","author":"Fujimoto","year":"2001","journal-title":"Qual Life Res"},{"key":"2020010903182658500_rrw122C18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0360-3016(01)01707-2","article-title":"A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy","volume":"51","author":"Lee","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903182658500_rrw122C19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2013.08.019","article-title":"Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials","volume":"87","author":"King","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020010903182658500_rrw122C20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.clon.2013.01.001","article-title":"Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomized trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy","volume":"25","author":"Hoskin","year":"2013","journal-title":"Clin Oncol"},{"issue":"Suppl 5","key":"2020010903182658500_rrw122C21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bju.12964","article-title":"Adverse effects of androgen-deprivation therapy in prostate cancer and their management","volume":"115","author":"Rhee","year":"2015","journal-title":"BJU Int"},{"key":"2020010903182658500_rrw122C22","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jrr\/article-pdf\/58\/2\/260\/31614779\/rrw122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jrr\/article-pdf\/58\/2\/260\/31614779\/rrw122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T03:25:11Z","timestamp":1578540311000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/58\/2\/260\/2769518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,1,11]]},"published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rrw122","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,3]]},"published":{"date-parts":[[2017,1,11]]}}}